Veeva Systems (NYSE:VEEV – Get Free Report) and Aclarion (NASDAQ:ACON – Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, valuation, risk, institutional ownership, analyst recommendations, earnings and profitability.
Valuation & Earnings
This table compares Veeva Systems and Aclarion”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Veeva Systems | $3.20 billion | 15.45 | $908.91 million | $6.08 | 50.15 |
| Aclarion | $80,000.00 | 58.97 | -$7.23 million | ($7.40) | -0.22 |
Veeva Systems has higher revenue and earnings than Aclarion. Aclarion is trading at a lower price-to-earnings ratio than Veeva Systems, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Veeva Systems and Aclarion’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Veeva Systems | 29.34% | 14.25% | 11.71% |
| Aclarion | -10,215.15% | -62.91% | -59.33% |
Analyst Ratings
This is a breakdown of recent ratings for Veeva Systems and Aclarion, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Veeva Systems | 1 | 8 | 19 | 0 | 2.64 |
| Aclarion | 1 | 0 | 1 | 0 | 2.00 |
Veeva Systems currently has a consensus price target of $317.42, suggesting a potential upside of 4.09%. Aclarion has a consensus price target of $7.50, suggesting a potential upside of 357.88%. Given Aclarion’s higher possible upside, analysts clearly believe Aclarion is more favorable than Veeva Systems.
Volatility & Risk
Veeva Systems has a beta of 0.89, indicating that its share price is 11% less volatile than the S&P 500. Comparatively, Aclarion has a beta of 1.21, indicating that its share price is 21% more volatile than the S&P 500.
Institutional and Insider Ownership
88.2% of Veeva Systems shares are owned by institutional investors. Comparatively, 7.5% of Aclarion shares are owned by institutional investors. 10.6% of Veeva Systems shares are owned by company insiders. Comparatively, 0.0% of Aclarion shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Summary
Veeva Systems beats Aclarion on 11 of the 14 factors compared between the two stocks.
About Veeva Systems
Veeva Systems Inc. develops cloud-based software, data and consulting services for the life sciences industry. Its customers include pharmaceutical and biotechnology companies, medical device makers and contract research organizations. The company’s products support commercial operations as well as clinical, regulatory, quality and safety activities. Its offerings include Veeva Vault applications for managing documents and business processes, customer relationship management software, and data and analytics services.
About Aclarion
Aclarion, Inc. is a medical technology company focused on improving the diagnosis and treatment of chronic low back pain. The company develops data-driven tools intended to help physicians identify the spinal discs most likely to be contributing to a patient’s pain and support more informed treatment decisions. Its principal product is Nociscan, a cloud-based software platform that analyzes magnetic resonance spectroscopy data from the spine. Using proprietary algorithms and chemical biomarkers associated with disc degeneration, Nociscan is designed to provide information about disc health and help distinguish potentially painful discs from discs that may not be the primary source of symptoms.
Receive News & Ratings for Veeva Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veeva Systems and related companies with MarketBeat.com's FREE daily email newsletter.
